The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine
Open accessAbstract
Abstract. Chao C, Klein NP, Velicer CM, Sy LS, Slezak JM, Takhar H, Ackerson B, Cheetham TC, Hansen J, Deosaransingh K, Emery M, Liaw K‐L, Jacobsen SJ (Kaiser Permanente Southern California, Pasadena, CA; Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California, Oakland, CA; Merck Research Laboratories, Upper Gwynedd, PA; South Bay Medical Center, Kaiser Permanente Southern California, Los Angeles, CA; and Kaiser Permanente Southern California, Downey, CA, USA). Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med 2012; 271: 193–203. Objective. An observational safety study of the quadrivalent human papillomavirus vaccine (HPV4) in women was conducted. This report presents findings from autoimmune surveillance. Design. Subjects were followed for 180 days after each HPV4 dose for new diagnoses of 16 prespecified autoimmune conditions. Setting. Two managed care organizations in California. Subjects. Number of 189 629 women who received ≥1 dose of HPV4 between 08/2006 and 03/2008. Outcome. Potential new‐onset autoimmune condition cases amongst HPV4 recipients were identified by electronic medical records. Medical records of those with ≥12‐month health plan membership prior to vaccination were reviewed by clinicians to confirm the diagnosis and determine the date of disease onset. The incidence of each autoimmune condition was estimated for unvaccinated women at one study site using multiple imputations and compared with that observed in vaccinated women. Incidence rate ratios (IRR) were calculated. Findings were reviewed by an independent Safety Review Committee (SRC). Results. Overall, 1014 potential new‐onset cases were electronically identified; 719 were eligible for case review; 31–40% were confirmed as new onset. Of these, no cluster of disease onset in relation to vaccination timing, dose sequence or age was found for any autoimmune condition. None of the estimated IRR was significantly elevated except Hashimoto’s disease [IRR = 1.29, 95% confidence interval: 1.08–1.56]. Further investigation of temporal relationship and biological plausibility revealed no consistent evidence for a safety signal for autoimmune thyroid conditions. The SRC and the investigators identified no autoimmune safety concerns in this study. Conclusions. No autoimmune safety signal was found in women vaccinated with HPV4.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Garland, S. M., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Harper, D. M., Leodolter, S., Tang, G. W. K., Ferris, D. G., Steben, M., Bryan, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061760 · Cited by 1,886
The Vaccine Adverse Event Reporting System (VAERS)
CHEN, R., RASTOGI, S., MULLEN, J., HAYES, S., COCHI, S., DONLON, J., & WASSILAK, S. (1994) · Vaccine · doi:10.1016/0264-410x(94)90315-8 · Cited by 498
Cited by
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
Joura, E. A., Giuliano, A. R., Iversen, O.-E., Bouchard, C., Mao, C., Mehlsen, J., Moreira, E. D., Ngan, Y., Petersen, L. K., Lazcano-Ponce, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1405044 · Cited by 1,433
Furer, V., Rondaan, C., Heijstek, M. W., Agmon-Levin, N., van Assen, S., Bijl, M., Breedveld, F. C., D'Amelio, R., Dougados, M., Kapetanovic, M. C., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215882 · Cited by 829
Arbyn, M., Xu, L., Simoens, C., & Martin-Hirsch, P. P. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009069.pub3 · Cited by 621
Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)
Shimabukuro, T. T., Nguyen, M., Martin, D., & DeStefano, F. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.07.035 · Cited by 608
Human Papillomavirus Vaccine Introduction – The First Five Years
Markowitz, L. E., Tsu, V., Deeks, S. L., Cubie, H., Wang, S. A., Vicari, A. S., & Brotherton, J. M. L. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.05.039 · Cited by 364
Metadata
- Authors
- Chao, C., Klein, N. P., Velicer, C. M., Sy, L. S., Slezak, J. M., Takhar, H., Ackerson, B., Cheetham, T. C., Hansen, J., Deosaransingh, K., Emery, M., Liaw, K. ‐., & Jacobsen, S. J.
- Venue
- Journal of Internal Medicine
- Publisher
- Wiley
- Published
- 2011-11-15
- Volume
- 271
- Issue
- 2
- Pages
- 193-203
- ISSN
- 0954-6820 (ISSN-L)
- 1365-2796
- OpenAlex
- W1519091069
- Cited by
- 199
- References
- 2
- FWCI
- 12.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. https://app.cochat.ai/papers/10.1111/j.1365-2796.2011.02467.x
- The paper
- Chao, C., Klein, N. P., Velicer, C. M., Sy, L. S., Slezak, J. M., Takhar, H., Ackerson, B., Cheetham, T. C., Hansen, J., Deosaransingh, K., Emery, M., Liaw, K. ‐., & Jacobsen, S. J. (2012). Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. Journal of Internal Medicine. https://doi.org/10.1111/j.1365-2796.2011.02467.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.